GlassScriptPhysician profile
Jaspal Singh
NPI 1720010895
$190,515.05
in general payments reported to CMS, 2019-2025
38 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,262 · 2020: $19K · 2021: $11K · 2022: $35K · 2023: $45K · 2024: $33K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $95K · Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,620 · Travel and Lodging: $3,528 · Food and Beverage: $3,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $94,500.00 |
| Consulting Fee | $13,987.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,620.00 |
| Travel and Lodging | $3,527.98 |
| Food and Beverage | $3,321.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $127,929.33 | 2019-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $32,290.69 | 2020-2024 | Tagrisso, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,767.23 | 2020-2025 | Jardiance, Glyxambi |
| Janssen Scientific Affairs, LLC | $4,992.60 | 2025 | |
| Siemens Medical Solutions USA, INC. | $4,937.09 | 2021-2025 | Cios Spin |
| Medtronic, INC. | $4,337.22 | 2021-2025 | Intellis Adaptivestim, Illumisite |
| Regeneron Healthcare Solutions, INC. | $1,602.00 | 2023 | Libtayo |
| Pulmonx Corporation | $1,497.86 | 2020-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Ethicon INC. | $1,159.49 | 2020-2022 | |
| Galvanize Therapeutics, INC | $320.25 | 2023-2025 | Aliya System |
| Inspire Medical Systems, INC. | $217.37 | 2023-2024 | Inspire |
| Covidien LP | $215.70 | 2019 | |
| United Therapeutics Corporation | $210.70 | 2022-2025 | Tyvaso |
| La Jolla Pharmaceutical Company | $107.41 | 2019-2020 | |
| Melinta Therapeutics, LLC | $98.98 | 2020-2023 | Kimyrsa, Vabomere |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $98.33 | 2022-2023 | Nucala |
| Olympus America INC. | $91.86 | 2024-2025 | Spiration Valve System, Visiglide |
| Bard Access Systems, INC. | $90.41 | 2019 | |
| Pinnacle Biologics, INC | $61.41 | 2025 | Photofrin |
| Novartis Pharmaceuticals Corporation | $49.80 | 2019 | |
| Lilly USA, LLC | $49.16 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $47.08 | 2019-2023 | Keytruda |
| Genzyme Corporation | $42.17 | 2021-2022 | |
| Janssen Biotech, INC. | $40.08 | 2023 | |
| Cook Medical LLC | $36.67 | 2020 | |
| Amarin Pharma, INC. | $35.58 | 2020-2021 | |
| Advanced Respiratory, INC | $31.09 | 2020-2021 | |
| Mylan Specialty L.P. | $29.68 | 2021 | |
| Amgen INC. | $23.59 | 2023 | Lumakras |
| Baxter Healthcare | $23.42 | 2023 | Hillrom - Volara System |
| Alexion Pharmaceuticals, INC. | $17.67 | 2022 | |
| Ekos Corporation | $16.29 | 2019 | |
| Grifols USA, LLC | $16.24 | 2022 | |
| Boston Scientific Corporation | $14.36 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Veran Medical Technologies, INC. | $4.32 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.